Genomic Classification of Cutaneous Melanoma.

PubWeight™: 3.91‹?› | Rank: Top 1%

🔗 View Article (PMID 26091043)

Published in Cell on June 18, 2015


Cancer Genome Atlas Network

Articles citing this

(truncated to the top 100)

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science (2015) 4.88

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell (2016) 2.65

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell (2016) 2.39

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet (2016) 2.28

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95

Whole-genome landscapes of major melanoma subtypes. Nature (2017) 1.40

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov (2015) 1.30

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet (2015) 1.24

Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget (2016) 1.17

Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. Nat Genet (2016) 1.11

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet (2016) 1.05

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med (2016) 1.01

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun (2015) 1.01

Targeting the cancer epigenome for therapy. Nat Rev Genet (2016) 1.01

Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. Proc Natl Acad Sci U S A (2016) 1.00

Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget (2016) 0.98

Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations. Elife (2017) 0.97

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest (2016) 0.93

Cancer immunotherapy targeting neoantigens. Semin Immunol (2015) 0.92

INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma. Genes Dev (2016) 0.91

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst (2016) 0.91

The role of neoantigens in response to immune checkpoint blockade. Int Immunol (2016) 0.90

High-resolution interrogation of functional elements in the noncoding genome. Science (2016) 0.90

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunol Res (2016) 0.88

From melanocytes to melanomas. Nat Rev Cancer (2016) 0.85

State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin (2016) 0.85

The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. Mod Pathol (2016) 0.84

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A (2016) 0.84

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget (2016) 0.83

Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. Nat Rev Clin Oncol (2016) 0.83

ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med (2016) 0.83

Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest (2016) 0.82

Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. World J Clin Oncol (2016) 0.82

A PGC1α-mediated transcriptional axis suppresses melanoma metastasis. Nature (2016) 0.82

ccmGDB: a database for cancer cell metabolism genes. Nucleic Acids Res (2015) 0.81

Genetics of melanocytic nevi. Pigment Cell Melanoma Res (2015) 0.81

The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol (2016) 0.81

The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. Cold Spring Harb Perspect Med (2016) 0.81

Melanoma genome evolution across species. BMC Genomics (2017) 0.81

Regulatory circuits of T cell function in cancer. Nat Rev Immunol (2016) 0.81

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80

Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us? Cancers (Basel) (2015) 0.80

Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi. J Invest Dermatol (2016) 0.80

Precision medicine from the renal cancer genome. Nat Rev Nephrol (2016) 0.80

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med (2017) 0.80

Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun (2016) 0.80

Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing. Am J Hum Genet (2016) 0.79

Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res (2017) 0.79

TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget (2016) 0.79

Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. Am J Surg Pathol (2016) 0.79

Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology (2016) 0.79

Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget (2016) 0.79

RMEL3, a novel BRAFV600E-associated long noncoding RNA, is required for MAPK and PI3K signaling in melanoma. Oncotarget (2016) 0.79

Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics. Oncotarget (2016) 0.79

BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance. Genes Dev (2015) 0.79

Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics (2016) 0.78

Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. Elife (2016) 0.78

Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. Mol Cancer Res (2016) 0.78

Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1. Mol Cell Biol (2016) 0.78

Frequent DPH3 promoter mutations in skin cancers. Oncotarget (2015) 0.78

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide. Oncotarget (2015) 0.78

Identification of a Novel Pathogenic Germline KDR Variant in Melanoma. Clin Cancer Res (2015) 0.78

The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. Lab Invest (2017) 0.78

Fluorescence in situ hybridization in surgical pathology: principles and applications. J Pathol Clin Res (2017) 0.78

Cross-species models of human melanoma. J Pathol (2015) 0.77

Tissue-specific tumorigenesis: context matters. Nat Rev Cancer (2017) 0.77

Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts. Oncotarget (2016) 0.77

Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V'DJer. Bioinformatics (2016) 0.77

Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. Semin Oncol (2016) 0.77

MutationAligner: a resource of recurrent mutation hotspots in protein domains in cancer. Nucleic Acids Res (2015) 0.77

Association of TERT promoter mutations with telomerase expression in melanoma. Pigment Cell Melanoma Res (2016) 0.77

Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies. Oncotarget (2016) 0.77

Revisiting determinants of prognosis in cutaneous melanoma. Cancer (2015) 0.77

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Rep (2016) 0.77

ELF5 isoform expression is tissue-specific and significantly altered in cancer. Breast Cancer Res (2016) 0.77

TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages. F1000Res (2016) 0.77

Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol (2017) 0.77

WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner. Oncogene (2017) 0.77

Searching for the Chokehold of NRAS Mutant Melanoma. J Invest Dermatol (2016) 0.77

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature (2017) 0.76

A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants. Int J Cancer (2016) 0.76

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (2017) 0.76

Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell (2017) 0.76

Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. J Clin Invest (2017) 0.76

Oncogenic RAS regulates long non-coding RNA Orilnc1 in human cancer. Cancer Res (2017) 0.76

SOX5 is involved in balanced MITF regulation in human melanoma cells. BMC Med Genomics (2016) 0.76

Investigating cellular network heterogeneity and modularity in cancer: a network entropy and unbalanced motif approach. BMC Syst Biol (2016) 0.76

The utility of transposon mutagenesis for cancer studies in the era of genome editing. Genome Biol (2015) 0.76

RASopathy Gene Mutations in Melanoma. J Invest Dermatol (2016) 0.76

Murine melanomas accelerated by a single UVR exposure carry photoproduct footprints but lack UV signature C>T mutations in critical genes. Oncogene (2015) 0.76

Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq. Oncotarget (2016) 0.76

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Ann Transl Med (2015) 0.76

Metabolic rewiring in melanoma. Oncogene (2016) 0.76

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget (2016) 0.76

The prognostic potential of alternative transcript isoforms across human tumors. Genome Med (2016) 0.76

DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Rep (2016) 0.76

Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer (2016) 0.76

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76

Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep (2016) 0.75

The NF1 gene in tumor syndromes and melanoma. Lab Invest (2017) 0.75

Articles cited by this

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16

Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12

A landscape of driver mutations in melanoma. Cell (2012) 12.61

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68

Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02

Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87

Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 8.63

Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48

Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40

TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62

Second primary neoplasms in patients with retinoblastoma. Br J Cancer (1986) 3.57

KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49

Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17

Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16

Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10

Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med (2011) 3.10

Melanoma: from mutations to medicine. Genes Dev (2012) 2.59

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49

Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32

Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest (1996) 2.31

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol (2012) 2.17

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res (2008) 1.98

Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90

ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med (2014) 1.66

Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol (2010) 1.65

Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62

Melanoma thickness trends in the United States, 1988-2006. J Invest Dermatol (2009) 1.60

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55

Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53

UV signature mutations. Photochem Photobiol (2014) 1.52


Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45

Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol (2013) 1.38

Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol (2012) 1.21

Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol (2014) 1.13

IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem Biophys Res Commun (2010) 1.08

Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem (2014) 1.08

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res (2014) 1.08

Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990-2006. Int J Cancer (2011) 1.06

Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol (2010) 0.99

Integrative genomics identifies gene signature associated with melanoma ulceration. PLoS One (2013) 0.95

Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res (2013) 0.95

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib. Pigment Cell Melanoma Res (2014) 0.94

PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition. Mol Cancer Res (2013) 0.94

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One (2014) 0.93

A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget (2014) 0.92

Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin. J Cutan Pathol (1997) 0.90